Why Treat Latent TB Infection When You Feel Well?

TB CHOICE NOTES 5 / 9

If you feel well after being told you have latent TB infection, the reason for taking medicine may not be immediately clear. With no cough and no risk of passing LTBI to your family, it is natural to wonder whether treatment is worth the inconvenience and possible side effects. LTBI treatment aims to lower the risk of developing active TB disease in the future, rather than to relieve symptoms you have now. 3

Avoid either starting medicine on the strength of the word “positive” alone or deciding that treatment is unnecessary because you feel well. First, clinicians need to assess whether active TB disease is present, then discuss your risk of developing disease and the factors that matter during treatment. Rather than choosing a particular medicine or duration, this article explains the purpose and the questions to bring to your appointment. 1

1. What can treatment change if you have no symptoms?

Latent TB infection (LTBI) means infection with TB bacteria without active TB disease. LTBI itself cannot spread to other people, but some people develop TB disease later. Treatment aims to reduce that possibility of infection progressing to disease. It is not a punishment or a form of isolation based on the idea that you are currently a danger to others. 3 5

Unlike the relief you might notice from a cold medicine, the benefit of preventive treatment is not usually something you can feel immediately. Having no particular change in symptoms before and after treatment does not mean it has had no effect. Equally, feeling well now cannot guarantee that disease will never develop. A treatment decision considers future risk as well as current discomfort. 2 3

Read numerical descriptions of benefit carefully too. A study finding that treatment greatly reduces the risk of disease does not mean every treated person is left with the same absolute risk. Rather than offering a single percentage that may not fit your circumstances, the useful point here is that treatment lowers the risk but does not guarantee that it disappears completely. 5 3

2. Why must active TB disease be assessed first?

A positive IGRA or tuberculin skin test (TST) alone cannot distinguish LTBI from active TB disease. Clinicians review current symptoms, history and chest X-rays, and use additional tests, such as sputum testing, when needed. LTBI treatment alone may be inadequate if active TB disease is actually present, which makes the pretreatment assessment important. 1 4

If you have a positive report from years ago, explain when the test was done and whether you received treatment then. A past positive result does not replace an assessment of your current condition. KDCA's counseling casebook likewise explains that someone starting treatment long after diagnosis needs an assessment for active TB disease and a discussion of treatment based on their current risk. 2

If a new cough, fever, sweats or unexplained weight loss develops while you are waiting to start, report the change rather than simply attending to collect the medicines. Pretreatment checks are not a formality; they help establish which treatment is needed. “My last X-ray was fine” is not an explanation for a new symptom. 1 5

3. For whom might treatment benefits be particularly important?

Even with the same positive test result, the priority for discussion differs according to recent exposure to infectious TB and health conditions that make disease more likely after infection. Individual risk assessment is especially important for young children, people with weakened immunity and those preparing for immunosuppressive treatment. Asking “Why is treatment being recommended for me?” can explain more than the result alone. 1 4

The review considers more than benefit: age, existing conditions such as liver disease, interactions with other medicines, pregnancy or breastfeeding, and practical circumstances affecting treatment also matter. Older age or hepatitis does not automatically make treatment impossible. Conversely, considering yourself generally healthy does not establish that testing or follow-up is unnecessary. Benefits and risks need to be weighed for your circumstances. 1 2

Be specific about your concerns. “I am worried about my liver results,” “I already take several medicines” and “My work hours make visits difficult” describe different problems. They call for different safety checks or practical support. Discuss the main obstacle rather than postponing treatment without a clear plan. 2 4

4. Is it okay if your medicines or duration differ from someone else's?

LTBI treatment can involve different medicine combinations and schedules. Clinicians consider your health, other medicines, possible adverse effects and the likelihood of completing treatment. For a contact, the drug-susceptibility results of the person identified in the investigation as the source of exposure are also important. These tests assess whether the TB bacteria respond to particular medicines; resistance can change the treatment choices. 1

A friend having a shorter course does not mean yours should be shortened, and a longer course does not by itself mean your condition is more severe. Regimens recommended on websites from other countries are not a prescription menu that everyone in Korea can immediately choose from. Ask why the plan fits your situation and what would prompt it to be reviewed, rather than comparing medicine names online. 1 4

Write down the expected schedule, next visit, necessary tests and how completion will be assessed. Mention planned travel, a move or treatment for another illness before starting. If the schedule needs adjustment, work it out with the team rather than splitting doses or extending the intervals yourself. 3

5. What safety plan should you have before starting?

Prepare a list of everything you take, including prescriptions, nonprescription medicines, supplements and traditional herbal medicines. If you cannot remember the names, bring prescriptions or photographs of the packaging. Alcohol use, past adverse drug reactions, liver disease, possible pregnancy and breastfeeding should also be discussed. The tests and frequency of follow-up can vary, so do not simply copy another person's testing schedule. 1 3

Completing treatment does not mean tolerating severe adverse reactions. Before starting, ask whom to contact immediately and what to do that day if you develop concerning symptoms such as jaundice, persistent severe nausea or abdominal pain, or changes in vision. Stopping, restarting or changing doses should follow the team's advance or same-day safety instructions. This does not mean continuing to take medicines regardless of a suspected significant adverse reaction while waiting to reach the team. Check the safety instructions for the next dose and seek prompt assessment. Medicine safety is covered in more detail in article 7 of this series. 4

Also obtain instructions for missed doses before treatment begins. Do not improvise by doubling a dose or taking several missed days' medicines together. Record the missed dates and the time of your last dose and tell the team, so clinicians can decide whether the schedule needs adjustment. Alarms and medicine charts can help you follow the plan; they do not determine changes to the prescription. 3

6. How is treatment completion confirmed?

IGRA and TST results may remain positive after LTBI treatment. These immune-response tests do not reliably turn negative in line with treatment success, so a positive result alone does not establish treatment failure. Repeating an infection test to measure the outcome of LTBI treatment is not an appropriate way to assess it. The treating clinician reviews whether the prescribed treatment has been followed and completed. 2

When you take the last dose, ask whether completion has been confirmed and which records to keep. Documentation of the diagnostic test, medicines, treatment period and completion status can help when you attend another service later. New TB exposure or symptoms still need advice after completion. Treatment does not guarantee protection against every future new infection. 3 4

Practical checklist

• I have checked whether the assessment to rule out active TB disease is complete.
• I have asked why treatment is recommended for me and discussed its benefits and risks.
• I have reported existing conditions, pregnancy or breastfeeding, all medicines and previous adverse reactions.
• I have written down why this regimen was chosen and the visit and testing schedule.
• I have contact details and individual instructions for adverse reactions or missed doses.
• I know how completion will be confirmed and which records to keep.

Common questions

Q1. Must I avoid my family while receiving LTBI treatment?

If active TB disease has been ruled out and LTBI diagnosed, LTBI itself is not infectious. Receiving treatment does not mean that infectious TB disease has developed. Seek separate advice if new symptoms appear. 5

Q2. What if fear of side effects has stopped me from deciding?

Discuss your concerns openly and revisit your risk of disease, possible treatment choices and monitoring. If you and the clinician agree to defer treatment, also establish which symptoms to report and when to reassess. Keeping the test report without any follow-up plan should not be the end of the discussion. 2

Q3. My positive result was years ago. Is it too late for treatment?

Time passing does not automatically make treatment pointless. You do, however, need a new assessment for current active TB disease and your present risk of developing it. Bring the earlier result, treatment history and information about any later exposures. 2

This article provides general health information. It does not decide an individual's need for treatment, medicine, dose or duration. Report concerning symptoms during treatment promptly to the team. Do not change the prescription yourself; follow the team's safety instructions.

Sources checked: 24 October 2026 KST / 23 October 2026 UTC

Official sources

1. KDCA, 2026 National Tuberculosis Control Guidelines (in Korean): Pretreatment assessment, treatment selection and management, printed pp. 106–109.
2. KDCA, 2026 Standard Counseling Casebook for TB and LTBI Management (in Korean): Individual counseling and assessment of treatment completion in Q108, Q110 and Q113–117.
3. CDC, Treating Inactive Tuberculosis: The purpose of LTBI treatment, medicine-taking and records. “Inactive TB” here means latent TB infection.
4. CDC, Treatment for Latent Tuberculosis Infection: Ruling out active TB disease, interactions, monitoring and post-treatment records. US regimens are not presented as prescriptions for use in Korea.
5. WHO, Tuberculosis: Infection, disease and the purpose of preventive treatment.